Immune checkpoint inhibitors for multiple myeloma immunotherapy

被引：13
|
作者：
Liu, Zhaoyun [1 ]
Xu, Xintong [1 ]
Liu, Hui [1 ]
Zhao, Xianghong [1 ]
Yang, Chun [1 ]
Fu, Rong [1 ]
机构：
[1] Tianjin Med Univ, Gen Hosp, Dept Hematol, Tianjin 300052, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
基金：
中国国家自然科学基金;
关键词：
Immune checkpoint; CTLA-4; TIGIT; Multiple myeloma; treatment strategy; T-LYMPHOCYTE ATTENUATOR; KIR ANTIBODY IPH2101; PHASE-I TRIAL; PD-1; BLOCKADE; DARATUMUMAB MONOTHERAPY; ANTITUMOR IMMUNITY; B-LYMPHOCYTE; PLASMA-CELLS; EXPRESSION; CANCER;
D O I：
10.1186/s40164-023-00456-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multiple myeloma (MM) is related to immune disorders, recent studys have revealed that immunotherapy can greatly benefit MM patients. Immune checkpoints can negatively modulate the immune system and are closely associated with immune escape. Immune checkpoint-related therapy has attracted much attention and research in MM. However, the efficacy of those therapies need further improvements. There need more thoughts about the immune checkpoint to translate their use in clinical work. In our review, we aggregated the currently known immune checkpoints and their corresponding ligands, further more we propose various ways of potential translation applying treatment based on immune checkpoints for MM patients.
引用
收藏
页数：20
相关论文
共 50 条
  • [41] Impact of Immune Checkpoint Inhibitors on the Course of Multiple Sclerosis
    Androdias, Geraldine
    Noroy, Louise
    Psimaras, Dimitri
    Birzu, Cristina
    Pelletier, Jean
    Beigneux, Ysoline
    Branger, Pierre
    Ciron, Jonathan
    Dananchet, Yannick
    Depaz, Raphael
    Tilikete, Caroline Froment
    Gignoux, Laurence
    Grosset-Janin, Clara
    Joubert, Bastien
    Kerschen, Philippe
    Kwiatkowski, Arnaud
    Lebrun-Frenay, Christine
    Maillart, Elisabeth
    Maureille, Aurelien
    Nicolas, Philippe
    Roux, Thomas
    Marignier, Romain
    Vukusic, Sandra
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (02): : e200202
  • [42] Multiple endocrinopathies in a patient treated with immune checkpoint inhibitors
    Hakami, O. A.
    Kgosidialwa, O.
    Grogan, L.
    Agha, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2019, 188 : S229 - S229
  • [43] LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
    Ibrahim, Rebecca
    Saleh, Khalil
    Chahine, Claude
    Khoury, Rita
    Khalife, Nadine
    Cesne, Axel Le
    BIOMEDICINES, 2023, 11 (07)
  • [44] Statins and immune checkpoint inhibitors: a strategy to improve the efficacy of immunotherapy for cancer?
    Vos, Winnie G.
    Lutgens, Esther
    Seijkens, Tom T. P.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [45] What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?
    Douchet, Gaelle
    Aspeslagh, Sandrine
    BULLETIN DU CANCER, 2017, 104 (05) : 485 - 493
  • [46] Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.
    Singh, Harpreet
    Madan, Ravi Amrit
    Dahut, William L.
    Coyne, Geraldine Helen O'Sullivan
    Rauckhorst, Myrna
    McMahon, Sheri
    Heery, Christopher Ryan
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [47] Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer.
    Singh, Harpreet
    Madan, Ravi Amrit
    Dahut, William L.
    Strauss, Julius
    Rauckhorst, Myrna
    McMahon, Sheri
    Heery, Christopher Ryan
    Schlom, Jeffrey
    Gulley, James L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
    Shen, Pan
    Deng, Xuan
    Hu, Zhishuo
    Chen, Zhe
    Huang, Yao
    Wang, Ke
    Qin, Kai
    Huang, Ying
    Ba, Xin
    Yan, Jiahui
    Han, Liang
    Tu, Shenghao
    FRONTIERS IN MEDICINE, 2021, 8
  • [49] Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure
    Hernando-Calvo, A.
    Valdivia, A.
    Santa Gadea, O. Saavedra
    Brana, I.
    Berche, R.
    Matos, I.
    Vieito, M.
    Azaro Pedrazzoli, A. B.
    Alonso Casal, G.
    Galvao, V.
    Diez Garcia, M.
    Verdaguer, H.
    Ortiz Velez, C.
    Gonzalez, M.
    Baraibar Argota, I.
    Callejo, A.
    Munoz Couselo, E.
    Tabernero, J.
    Dienstmann, R.
    Garralda, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S489 - S490
  • [50] Acquired resistance for immune checkpoint inhibitors in cancer immunotherapy: challenges and prospects
    Chen, Xunrui
    Zhang, Wenhui
    Yang, Wenyan
    Zhou, Min
    Liu, Feng
    AGING-US, 2022, 14 (02): : 1048 - 1064
12345